/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Medicinova Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.51 0.0272(2.72%) MNOV at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 1.475
Highest Today 1.505
Today’s Open 1.48
Prev. Close 1.47
52 Week High 2.37
52 Week Low 1.13
Day’s Range: Low 1.475 High 1.505
52-Week Range: Low 1.13 High 2.37
1 day return -
1 Week return +5.63
1 month return +4.16
3 month return +11.11
6 month return +7.14
1 year return -33.62
3 year return -39.75
5 year return -75.36
10 year return -

Institutional Holdings

Essex Woodlands Health Ventures 2.25

BlackRock Inc 1.42

Vanguard Group Inc 1.40

Citigroup Inc 1.21

Geode Capital Management, LLC 1.07

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Fidelity Extended Market Index 0.54

Susquehanna International Group, LLP 0.51

UBS Group AG 0.45

Renaissance Technologies Corp 0.36

State Street Corp 0.36

Northern Trust Corp 0.28

Barclays PLC 0.22

iShares Micro-Cap ETF 0.21

Bank of New York Mellon Corp 0.20

Bank of America Corp 0.19

Fidelity Total Market Index 0.18

Extended Equity Market Fund K 0.17

Bridgeway Capital Management, LLC 0.16

Charles Schwab Investment Management Inc 0.15

Schwab Total Stock Market Index 0.15

Bridgeway Ultra-Small Company Market 0.14

Dimensional Fund Advisors, Inc. 0.14

Fidelity Series Total Market Index 0.13

Spartan Extended Market Index Pool F 0.11

SBI Securities Co Ltd 0.09

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

NT Ext Equity Mkt Idx Fd - NL 0.07

Schonfeld Strategic Advisors LLC 0.07

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Fidelity Nasdaq Composite Index 0.05

Spartan Total Market Index Pool G 0.05

Vanguard U.S. Eq Idx £ Acc 0.03

Northern Small Cap Core I 0.03

Dimensional US Core Equity 2 ETF 0.03

Dimensional Global Core Equity USD Acc 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Hantz Financial Services, INC. 0.01

Tower Research Capital LLC 0.01

Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 72.10 M

PB Ratio 1.5841

PE Ratio 0.0

Enterprise Value 37.26 M

Total Assets 55.88 M

Volume 77181

Company Financials

Annual Revenue FY24:0 0.0M, FY23:1000000 1.0M, FY22:0 0.0M, FY21:4037500 4.0M, FY20:0 0.0M

Annual Profit FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:4037500 4.0M, FY20:null 0.0M

Annual Net worth FY24:-11049549 -11.0M, FY23:-9513915 -9.5M, FY22:-14069083 -14.1M, FY21:-10134252 -10.1M, FY20:-13853897 -13.9M

Quarterly Revenue Q3/2025:123319 0.1M, Q2/2025:134599 0.1M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:-38957 -0.0M, Q2/2025:18250 0.0M, Q1/2025:-5177 -0.0M, Q4/2024:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q3/2025:-3050373 -3.1M, Q2/2025:-3281185 -3.3M, Q1/2025:-2864120 -2.9M, Q4/2024:-2814652 -2.8M, Q3/2024:-2852179000 -2852.2M

Fund house & investment objective

Company Information MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Dr. Yuichi Iwaki M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow